Stoke Therapeutics, Inc.

NasdaqGS:STOK Stock Report

Market Cap: US$1.6b

Stoke Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:STOK Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
22 Aug 25SellUS$18,500,000Skorpios TrustCompany1,000,000US$18.50
18 Aug 25SellUS$30,695Jonathan AllanIndividual1,683US$18.24
18 Aug 25SellUS$221,154Edward KayeIndividual12,126US$18.24
18 Aug 25SellUS$51,158Barry TichoIndividual2,805US$18.24
18 Jun 25SellUS$7,150,000Skorpios TrustCompany650,000US$11.00
04 Jun 25SellUS$30,600,000Skorpios TrustCompany3,000,000US$10.20
19 Mar 25SellUS$35,731Jonathan AllanIndividual4,211US$8.67
19 Mar 25SellUS$61,238Barry TichoIndividual7,217US$8.67
19 Mar 25SellUS$163,673Edward KayeIndividual19,289US$8.67
23 Dec 24SellUS$23,000,000Skorpios TrustCompany2,000,000US$11.50
09 Dec 24SellUS$88,158Edward KayeIndividual6,786US$12.99
09 Dec 24SellUS$20,164Jonathan AllanIndividual1,552US$12.99
09 Dec 24SellUS$33,596Barry TichoIndividual2,586US$12.99
06 Dec 24SellUS$78,837Edward KayeIndividual6,170US$12.78
06 Dec 24SellUS$123,891Jonathan AllanIndividual9,696US$12.78
06 Dec 24SellUS$178,182Barry TichoIndividual13,945US$12.78

Insider Trading Volume

Insider Buying: STOK insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of STOK?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders2,430,0093.7%
Hedge Funds14,133,29421.5%
Institutions49,183,77374.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 107.14% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
13.5%
FMR LLC
7,412,982US$222.7m192%0.01%
9.86%
Lynx1 Capital Management LP
5,404,674US$162.4m2.13%27.94%
9.35%
RTW Investments, LP
5,123,525US$153.9m0%1.74%
8.46%
Baker Bros. Advisors LP
4,633,838US$139.2m0%0.92%
7.99%
Redmile Group, LLC
4,375,931US$131.5m-2.45%9.44%
6.81%
BlackRock, Inc.
3,732,524US$112.1m-37%no data
6.5%
Morgan Stanley
3,562,271US$107.0m-0.51%0.01%
5.79%
Cowen Inc.
3,173,258US$95.3m0%7.4%
5.38%
The Vanguard Group, Inc.
2,946,258US$88.5m5.82%no data
4.2%
Marshall Wace LLP
2,300,554US$69.1m7.92%0.09%
4.12%
Skorpios Trust
2,256,181US$67.8m-30.7%99.74%
4.1%
Artal Group S.A.
2,247,347US$67.5m0%1.62%
3.42%
Seth Harrison
1,875,313US$56.3m0%no data
2.71%
State Street Global Advisors, Inc.
1,487,156US$44.7m-5.59%no data
2.11%
The Goldman Sachs Group, Inc.
1,153,504US$34.7m0%0.01%
1.78%
Geode Capital Management, LLC
972,921US$29.2m7.86%no data
1.64%
Assenagon Asset Management S.A.
900,272US$27.0m67.4%0.04%
1.61%
Polar Capital Holdings Plc
883,646US$26.5m0%0.07%
1.44%
MPM BioImpact LLC
789,698US$23.7m13.8%2.96%
1.23%
Dimensional Fund Advisors LP
673,884US$20.2m1.38%no data
1.2%
Corient Private Wealth LLC
659,834US$19.8m0%0.03%
1.03%
Opaleye Management Inc.
562,120US$16.9m87.4%2.67%
1%
Bank of America Corporation
548,090US$16.5m2.85%no data
0.97%
Granahan Investment Management, LLC
532,413US$16.0m-19.4%0.64%
0.92%
Dafna Capital Management, LLC
501,972US$15.1m13.1%3.26%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/31 17:35
End of Day Share Price 2025/10/31 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Stoke Therapeutics, Inc. is covered by 18 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gregory HarrisonBofA Global Research
Thomas ShraderBTIG
Michelle GilsonCanaccord Genuity